The leadership team brings a wealth of commercial experience, including expertise in successfully translating science and technology breakthroughs into the marketplace. This team is directing the commercialisation of Antoxis' Kromex platform and ensuring the Company has the financial resources it needs to succeed.

Prof. Andy Porter (FRSE)


Andy has a small number of additional non-executive Board positions within the biotechnology sector, and has established a specialist angel fund, Grampian BioPartners (GBP), investing in early stage Scottish biotechnology. A number of GBP companies have secured exits whilst others have products in Phase 2 trials. He was originally the founder and CSO of Haptogen Ltd, acquired by Wyeth Inc in October 2007. In 2005, he was made the Ernst and Young Plc, Science and Technology Entrepreneur of the Year. He has been a Fellow of the Royal Society of Edinburgh since 2006 and a Fellow of the Society of Biology since 2012.  

Malcolm Gillies


Malcolm is an active investor and business adviser who is involved with a number of private companies mainly in the biotech and mediscience sectors. He is a director of Aircraft Medical Limited (which produces sophisticated laryngoscopes and depth of anaesthesia monitoring devices); Ohmedics Limited (dealing with advanced wound management) and Recyclatech Group Limited (which commercialises the bacterial treatment of waste rubber materials). He was formerly a senior corporate finance partner with a large firm of solicitors and since retiring from the law has held other board appointments with Trading Emissions PLC (an AIM listed company trading carbon credits and related investments); IDMOS PLC (an AIM listed dental technology company) and Novabiotics Limited (a clinical stage biotechnology company). In addition, he acted for several years as part-time Company Secretary of Axis-Shield PLC, a medical diagnostics company listed in London and Oslo. He also has a number of charitable and other interests.

Douglas Thomson


Douglas joined as a Director in 2013. He has significant international experience as CEO, Business and Commercial Director of privately funded biotechnology companies having concluded over 50 deals with pharma, biotech and academic partners.Trained as an analytical chemist, previously, Douglas has worked for almost twenty years in a number of therapeutic biologics companies in executive, operational and commercial roles. He is Chairman and NXD of a number of biotech companies.

Dr Keith Winton 

Board Observer and Company Secretary

Keith was originally trained as a research chemist, but for a large proportion his working life he has been involved in the transfer of technology from the research base into the commercial world.  Initially, he was with Edinburgh University’s technology transfer office.  For the past decade, he has been managing seed and pre-seed capital funds to support early stage start-up companies emerging from the research base. His current focus is the Genomia Fund, which targets the funding gap facing the commercialisation of research emerging from a group of ten public sector research establishments working primarily in life and bio-sciences. Genomia provided the first investment into Antoxis. 

Donald McPhail

Scientific Consultant

Donald is a founder of Antoxis and inventor of its granted patents. A chemist by training, he worked at the Macaulay and Rowett Research Institutes in Aberdeen where he specialised in the application of electron spin resonance techniques to study free radical processes in biological systems. His main interests gravitated towards the role of phytochemical polyphenols in modulating cellular redox status, and the implications of this for human health. He developed internationally recognised methods to determine the antioxidant activity of dietary components with a particular interest in the relationship between chemical structure and antioxidant activity. With over 50 peer-reviewed journal publications he has been a member of four EU Commission Scientific Steering Committees. He was awarded a Royal Society of Edinburgh Enterprise Fellowship to establish Antoxis and commercialise its redox platform technology.